These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 15643299

  • 1. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity.
    Hift RJ, Meissner PN.
    Medicine (Baltimore); 2005 Jan; 84(1):48-60. PubMed ID: 15643299
    [Abstract] [Full Text] [Related]

  • 2. Medical and financial burden of acute intermittent porphyria.
    Neeleman RA, Wagenmakers MAEM, Koole-Lesuis RH, Mijnhout GS, Wilson JHP, Friesema ECH, Langendonk JG.
    J Inherit Metab Dis; 2018 Sep; 41(5):809-817. PubMed ID: 29675607
    [Abstract] [Full Text] [Related]

  • 3. Early administration of heme arginate for acute porphyric attacks.
    Mustajoki P, Nordmann Y.
    Arch Intern Med; 1993 Sep 13; 153(17):2004-8. PubMed ID: 8357285
    [Abstract] [Full Text] [Related]

  • 4. [Acute attacks of hepatic porphyria: specific treatment with heme arginate].
    Nordmann Y, Deybach JC.
    Ann Med Interne (Paris); 1993 Sep 13; 144(3):165-7. PubMed ID: 8368699
    [Abstract] [Full Text] [Related]

  • 5. Acute intermittent porphyria: fatal complications of treatment.
    Stein PE, Badminton MN, Barth JH, Rees DC, Sarkany R, Stewart MF, Cox TM.
    Clin Med (Lond); 2012 Jun 13; 12(3):293-4. PubMed ID: 22783787
    [Abstract] [Full Text] [Related]

  • 6. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
    To-Figueras J, Wijngaard R, García-Villoria J, Aarsand AK, Aguilera P, Deulofeu R, Brunet M, Gómez-Gómez À, Pozo OJ, Sandberg S.
    J Inherit Metab Dis; 2021 Jul 13; 44(4):961-971. PubMed ID: 33861472
    [Abstract] [Full Text] [Related]

  • 7. Best practice guidelines on clinical management of acute attacks of porphyria and their complications.
    Stein P, Badminton M, Barth J, Rees D, Stewart MF, British and Irish Porphyria Network.
    Ann Clin Biochem; 2013 May 13; 50(Pt 3):217-23. PubMed ID: 23605132
    [Abstract] [Full Text] [Related]

  • 8. [Favorable outcome of acute porphyric neuropathy after treatment with heme arginate].
    Diot E, Corcia P, Zannad N, Chauvet MA, Borie MJ, Maillot F.
    Rev Neurol (Paris); 2007 Nov 13; 163(11):1100-2. PubMed ID: 18033050
    [Abstract] [Full Text] [Related]

  • 9. Porphyric neuropathy: prevention of progression using haeme-arginate.
    Muthane UB, Vengamma B, Bharathi KC, Mamatha P.
    J Intern Med; 1993 Dec 13; 234(6):611-3. PubMed ID: 8258754
    [Abstract] [Full Text] [Related]

  • 10. Atypical attack of acute intermittent porphyria--paresis but no abdominal pain.
    Andersson C, Nilsson A, Bäckström T.
    J Intern Med; 2002 Sep 13; 252(3):265-70. PubMed ID: 12270008
    [Abstract] [Full Text] [Related]

  • 11. Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks.
    Puy H, Deybach JC, Baudry P, Callebert J, Touitou Y, Nordmann Y.
    Life Sci; 1993 Sep 13; 53(8):621-7. PubMed ID: 8350677
    [Abstract] [Full Text] [Related]

  • 12. [Anesthesia in patients with acute porphyria].
    Lederer D, Weigand MA, Larmann J.
    Anaesthesist; 2022 Apr 13; 71(4):321-330. PubMed ID: 35352131
    [Abstract] [Full Text] [Related]

  • 13. Severe porphyric neuropathy--importance of screening for porphyria in Guillain-Barré syndrome.
    Schutte CM, van der Meyden CH, van Niekerk L, Kakaza M, van Coller R, Ueckermann V, Oosthuizen NM.
    S Afr Med J; 2015 Nov 20; 106(1):44-7. PubMed ID: 26792303
    [Abstract] [Full Text] [Related]

  • 14. [Acute intermittent porphyria: a diagnostic dilemma].
    Gázquez Sisteré I, Luján Mavila K, Chordá Ribelles J, Touzón López C.
    Gastroenterol Hepatol; 2010 Nov 20; 33(6):436-9. PubMed ID: 20435380
    [Abstract] [Full Text] [Related]

  • 15. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases.
    Kauppinen R, Mustajoki P.
    Medicine (Baltimore); 1992 Jan 20; 71(1):1-13. PubMed ID: 1549056
    [Abstract] [Full Text] [Related]

  • 16. Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.
    Horie Y, Yasuoka Y, Adachi T.
    Orphanet J Rare Dis; 2023 Dec 08; 18(1):384. PubMed ID: 38066651
    [Abstract] [Full Text] [Related]

  • 17. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E, Harper P, Andersson DE, Floderus Y.
    Eur J Intern Med; 2009 Mar 08; 20(2):201-7. PubMed ID: 19327613
    [Abstract] [Full Text] [Related]

  • 18. Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations.
    Simon A, Pompilus F, Querbes W, Wei A, Strzok S, Penz C, Howe DL, Hungate JR, Kim JB, Agarwal S, Marquis P.
    Patient; 2018 Oct 08; 11(5):527-537. PubMed ID: 29915990
    [Abstract] [Full Text] [Related]

  • 19. Variegate porphyria.
    Mustajoki P.
    Ann Intern Med; 1978 Aug 08; 89(2):238-44. PubMed ID: 677592
    [Abstract] [Full Text] [Related]

  • 20. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.
    Prabahar MR, Manorajan R, Sathiyakumar D, Soundararajan P, Jayakumar M.
    Hemodial Int; 2008 Jan 08; 12(1):34-8. PubMed ID: 18271838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.